Cuprina Holdings Cayman Ltd (CUPR)

https://cuprina.com/

https://cuprina.com/governance

CUPR, Based in Singapore, we are a biotech company focusing on chronic wound care and cosmeceutical products, leveraging natural materials and biomedical research. Our MEDIFLY bio-dressing, a leader in Maggot Debridement Therapy, alongside pipeline products like bullfrog collagen dressings and medical leech products, underscore our commitment to innovation.

Zut!!! Actually, They're dumping huge shares!

Getting pumped and dumped? Hold it.

CUPR..............................https://stockcharts.com/sc3/ui/?s=CUPR&p=W&b=5&g=0&id=p86431144783

It was amazing run a/h yesterday. While it was as high as $9.5 last year, and even once went to $30 a/h last year.

Yep. It once went to $30 a/h last year, now just $0.4's, Over over sold. Will repeat !!!

CUPR once went to $30 a/h last year. Will it repeat?

CUPR............................a/h

CUPR.......................................https://stockcharts.com/sc3/ui/?s=CUPR&p=W&b=5&g=0&id=p86431144783

CUPR.................................................https://stockcharts.com/h-sc/ui?s=CUPR&p=W&b=5&g=0&id=p86431144783

CURP..............................................................bingo

$CUPR: Coollll.......... a CAYMAN Chiner now...........

Interesting................. so the chiners going thru the Cayman Islands route now.

Get your search buttons on "CAYMAN" now................ which is the next Cayman CHINER.


GO $CUPR

*****************************************************************************

Cuprina Secures Exclusive Rights to Southeast Asia's First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology
By Cuprina Holdings (Cayman) LTD | September 09, 2025, 8:05 AM

Share
CUPR
+12.23%
Cuprina Holdings (Cayman) Ltd
SINGAPORE, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it has secured exclusive licensing rights to Southeast Asia’s first medical waste recycling technology developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF), the major alliance supporting developing countries in achieving global environmental benefits.

The license, signed by Cuprina with China-based Zhejiang Heliang Technology Co., Ltd., covers Singapore and an option to expand into ten additional Southeast Asian countries.

As opposed to current medical waste technologies which incinerate waste and send its ash to landfills – a method that releases toxic emissions and strains Singapore’s already limited landfill capacity – the new technology uses advanced high-temperature steam treatment to sterilize and decontaminate medical waste, particularly plastic-based materials. Once clean, these materials are sorted and recycled into high-value resins and converted into sustainable raw materials that re-enter the economy.

The technology has gained validation over two decades via collaboration between Chinese authorities, UNIDO, and GEF, as well as via ISO certifications (9001, 14001, 45001) and extensive regulatory approvals.

Cuprina intends to apply for the operating licenses required in Singapore to construct a facility for the new technology, and is also engaging with the nation’s leading toxic waste disposal companies to integrate these processes seamlessly into the national waste management framework.

By establishing Singapore as the first hub for the technology outside of China, Cuprina aims to capture significant growth opportunities across Southeast Asia, where many governments are tightening environmental standards.

In Singapore, biohazardous medical waste increased from 4,400 tons in 2016 to 5,700 tons in 2020, an average annual increase of around 5%, driven by greater healthcare demand and tighter infection control measures (MOH Singapore).

According to a recent study by Grand View Research, the global medical waste management market was valued at USD 34.06 billion in 2023 and is projected to reach USD 59.42 billion by 2030, growing at 8% annually with Asia-Pacific the fastest-growing global region.

“This isn’t just about new equipment—it’s about bringing in a globally validated technology that has been refined, certified, and proven over two decades,” said Cuprina CEO David Quek Yong Qi. “By securing exclusive rights for Southeast Asia, Cuprina expects to lead the transition from incineration and landfill toward a new model that protects public health, safeguards the environment, and creates long-term value for our shareholders.”

About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards.

For more information, please visit https://cuprina.com/

FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com

Vaporizing medical waste has its privileges up300%

CUPR $$$ ON HUGE WATCH NEXT WEEK......

it also hit over 30 bucks a/h recently.

Wow stock in $9 range last week...now 1..holy macaroni

dip and rip, lets go

hoping….

i really do think it will run a/h.

they said, “We recognize that some investors have questions following Friday’s unusual trading activity. The Company is not aware of any operational reasons for this stock price volatility nor of any material adverse events which may have led to this activity. Let us be clear: Cuprina is operationally in a healthy position and is diligently executing on its business plan since the Company’s Initial Public Offering earlier this year. We are a Nasdaq-listed company with audited financials, an expanding footprint in Asia and beyond, and a pipeline of regulated medical products serving and benefitting real patients in need. Our team continues to work tirelessly to commercialize breakthrough biologics and scale our global partnerships. While share price volatility is largely outside of our control, execution and transparency remain firmly within it,” said David Quek, Chief Executive Officer and Executive Director of Cuprina.

The Company also emphasizes that, to its knowledge, none of the Company’s initial shareholders or founding team members have sold their stock over the past week. This underscores our collective confidence in the Company’s mission, strategy, and long-term growth potential.

The Company remains on track with its operational and regulatory milestones, including:
• Submission of FDA clearance for its medical maggot therapy;
• Expansion of maggot distribution to the Gulf Cooperation Council (GCC) region;
• Exploring potential joint ventures and mergers & acquisitions to build a continuum of care in chronic wound management products.

Cuprina will continue to keep shareholders updated on key developments and milestones through timely disclosures and filings. We deeply value the trust and support of our shareholders and are committed to communicating with transparency and integrity, and delivering on our business and market share growth as communicated to our valued shareholders.

yes, i took a screen shot of …..

…

it and i watched it run to 30 a/h, a few days ago. it wont show up on the reg charts but do the classic and click on 7 days.

CUPR $$$$ WAS IT TRADING AT $30+ RECENTLY, WAS THAT TRUE?, COULD SEE THE GAP CLOSE UP AFTER-HOURS...WOW !!!!

wow, tons of buying!

small shake and bake, lets go!

here we go, weeeee!!!!

this ran over 30 bucks a/h the other day.

cupr- grabbed some and I…

..

had to “create a board” as there was none for ihub.